Headache & Pain
News
First Patient Enrolled in Study of Oral CGRP Receptor Antagonist for Migraine
Tuesday, November 20, 2018—The first patient is enrolled in a phase 3 trial for the oral calcitonin gene-related peptide (CGRP) receptor antagonist rimegepant (Biohaven; New Haven, CT). The trial will a…
New Drug Application for Migraine Headache Therapy Lasmitidan
Monday, November 19, 2018—A New Drug Application (NDA) for lasmiditan (Eli Lilly and Company, Indianapolis, IN) has been submitted to the Food and Drug Administration (FDA). Lasmitidan is an investigat…
Migraines that Affect Vision May Increase Risk of Atrial Fibrillation
Thursday, November 15, 2018—People who experience migraine with visual aura may have an increased risk of atrial fibrillation (AFib), according to a study published in Neurology. Participan…
Study Confirms Benefits of Laser Interstitial Thermal Therapy
Wednesday, November 14, 2018—A prospective, multi-center clinical study of 42 patients with brain lesions that recurred after stereotactic radiosurgery (SRS) for metastatic brain tumors showed p…
Personal Pain Management App Approved for Use with Intrathecal Drug Delivery Pump
Wednesday, October 24, 2018—The US Food and Drug Administration (FDA) has approved use of an application (myPTM Personal Therapy Manager; Medtronic, Dublin, Ireland) for patients with chronic pain to use…
First Patient Treated in Trial of BHV-3500—A Nasally Delivered CGRP-Receptor Antagonist Being Investigated for Migraine
Tuesday, October 23, 2018—The first participant has been treated in a clinical trial of BHV-3500 (Biohaven, New Haven, CT) for the treatment of patients with migraine. The first intranasal formulation …
Medtronic Launches Control Workflow—An Evidence-Based Protocol for Use With Intrathecal Drug Delivery Pump for Effective Pain Relief
Friday, October 19, 2018—The Control Workflow system (Medtronic, Dublin, Ireland) is an evidence-based approach for use with the intrathecal drug delivery pump (SynchroMed II; Medtronic) to assist phy…
Safety Confirmed for Ubrogepant—A Small-Molecule Oral CGRP Receptor Antagonist for Treatment of Acute Migraine
Wednesday, October 17, 2018—Safety and tolerability studies have been completed for ubrogepant (Allergan, Dublin, Ireland) in patients with acute migraine over 1 year (NCT2867709) and in healthy voluntee…
